Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Dermatology

Your Treatment Plan: Halting the Progression

At a Glance

Frontal fibrosing alopecia treatment usually cannot regrow hair from permanently damaged follicles, but it can calm inflammation and help prevent further hairline loss. Doctors may combine oral and local medicines, with monitoring for side effects and stabilization over 6 to 12 months.

Treating Frontal Fibrosing Alopecia (FFA) requires a shift in perspective. Because the loss of hair follicles in FFA is permanent, the primary goal of modern treatment is stabilization—halting the inflammation to protect the hair you still have [1][2]. According to the 2025 Spanish Delphi consensus, an international panel of experts, a common approach involves individualized multimodal therapy, which means using several clinician-selected, often off-label treatments at the same time to manage the condition from multiple angles [1].

Treatment Strategy: The Foundation

The chosen treatment plan often begins with a combination of “systemic” (whole-body) medication and “local” (targeted) treatments [1]. Note that these treatments are generally prescribed off-label for FFA.

  • 5-Alpha Reductase Inhibitors (5-ARIs): Medications like dutasteride or finasteride are often used as systemic options [2][3]. In retrospective observational cohorts, they have been associated with stabilizing the progression of the hairline in approximately 62% to 64% of patients [4][5]. Stabilization means reducing the risk of further loss.
  • Local Anti-Inflammatories: To calm the redness and scaling at the hairline, doctors use topical corticosteroids (like clobetasol) or calcineurin inhibitors (like tacrolimus) [1][6].
  • Intralesional Steroids: Your doctor may inject a steroid called triamcinolone directly into the active edge of your hairline [1]. Some retrospective studies report slowing or arrest of hair loss in up to 88% of treated patients using this local measure [7].

Escalating Care

If inflammation persists despite initial treatment, or if you have specific symptoms like facial bumps, your doctor may recommend other medications [1].

  • Hydroxychloroquine: This is often considered if the scalp remains red or itchy [1]. While effective, it requires careful monitoring of your vision (see “Managing Risks” below) [8].
  • Oral Retinoids (Isotretinoin or Acitretin): These may be helpful if you have facial papules (small skin-colored bumps on the face) [6][9].
  • JAK Inhibitors: For cases that do not respond to traditional therapies (refractory cases), emerging treatments like JAK inhibitors (e.g., tofacitinib or baricitinib) are sometimes explored as specialist-directed, off-label options [10][11]. These drugs carry serious FDA “black box” warnings regarding severe infections, thrombosis, major cardiovascular events, and malignancy [10][12].

Managing Risks and Side Effects

Every effective treatment carries potential risks. Knowing what to watch for helps you stay safe while managing your hair loss. Contact your clinician if you experience severe symptoms.

Medication Potential Risks/Harms Required Monitoring & Precautions
Dutasteride / Finasteride Changes in libido or mood (rare in women); potential for severe birth defects in male fetuses [13][14]. Strict pregnancy prevention is required for those of childbearing age; pregnant individuals should not handle crushed tablets [14].
Hydroxychloroquine Retinal toxicity, which can lead to permanent vision loss if not caught early [8][15]. Requires a baseline eye exam before or near starting. Dose should be kept below 5 mg/kg of actual body weight. Follow-up screening frequency depends on dose and risk factors (e.g. kidney disease, tamoxifen use). Promptly report new visual changes [8][16].
Isotretinoin High risk of birth defects (teratogenicity); dry lips; potential mood changes; muscle aches; elevated liver enzymes or lipids [17][6][18][19]. Strict jurisdiction-specific pregnancy prevention program required. Baseline and periodic blood tests for liver and cholesterol [20][21]. (Acitretin has a substantially longer post-treatment pregnancy restriction).
Topicals Topical steroids can cause skin thinning (atrophy). Tacrolimus can cause initial burning or irritation. Follow specific dosing directions to prevent skin complications.
Steroid Injections Injection pain; skin atrophy (thinning of the skin or “dents”); loss of skin pigment (hypopigmentation) [22][23][24]. Your doctor will use lower concentrations (e.g., 2.5–5 mg/mL) and space out injections to reduce these risks [24][25].

It is important to remember that stabilization is a marathon, not a sprint. It can take 6 to 12 months of consistent treatment to determine if the disease has been successfully stabilized [4][26]. Regular check-ups with standardized photography and clinical evaluations are the best ways to ensure your plan is working [6].

Common questions in this guide

Can FFA treatment regrow hair that I have already lost?
Usually not. FFA can permanently destroy affected hair follicles, so treatment is intended mainly to calm inflammation and prevent additional hairline loss rather than restore hair from follicles that are already gone.
Why might my doctor use more than one FFA treatment at the same time?
FFA treatment may combine a whole-body medicine with topical treatment or steroid injections to address inflammation from different angles. The combination is individualized, and many FFA treatments are prescribed off-label.
How long does it take to tell whether FFA treatment is working?
It can take 6 to 12 months of consistent treatment to judge whether FFA has stabilized. Regular examinations and standardized photographs help your clinician compare the hairline over time.
What eye monitoring is needed if I take hydroxychloroquine for FFA?
A baseline eye exam is recommended before or near the time hydroxychloroquine is started, and follow-up screening depends on the dose and your risk factors. Clinicians generally keep the dose below 5 mg per kilogram of actual body weight, and new vision changes should be reported promptly because retinal damage can cause permanent vision loss.
What pregnancy precautions are needed with FFA medicines?
Dutasteride and finasteride can cause severe birth defects in a male fetus, while isotretinoin has a high risk of birth defects and acitretin requires a longer pregnancy restriction after treatment. Anyone who could become pregnant should follow the specific prevention program for the prescribed medicine, and pregnant people should not handle crushed dutasteride or finasteride tablets.
Which side effects should I report during FFA treatment?
Report new vision changes, significant mood changes, severe dryness, or other concerning symptoms to your clinician. Depending on the treatment, risks can include skin thinning or dents from steroid injections, irritation from topical medicines, and serious infections or blood clots with JAK inhibitors.

Get notified when new evidence is published on Frontal fibrosing alopecia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (26)
  1. 1

    Consensus Document on the Clinical Management of Frontal Fibrosing Alopecia: Recommendations From Spanish Working Group on Trichology and Onychology of the AEDV.

    Saceda-Corralo D, Combalia A, Fernandez-Crehuet P, et al.

    Actas dermo-sifiliograficas 2025; (117(1)):104486 doi:10.1016/j.ad.2025.104486.

    PMID: 41344613
  2. 2

    Frontal fibrosing alopecia: efficacy of treatment modalities.

    Gamret AC, Potluri VS, Krishnamurthy K, Fertig RM

    International journal of women's health 2019; (11()):273-285 doi:10.2147/IJWH.S177308.

    PMID: 31118828
  3. 3

    5-alpha-reductase inhibitor treatment for frontal fibrosing alopecia: an evidence-based treatment update.

    Murad A, Bergfeld W

    Journal of the European Academy of Dermatology and Venereology : JEADV 2018; (32(8)):1385-1390 doi:10.1111/jdv.14930.

    PMID: 29524253
  4. 4

    Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice.

    Pindado-Ortega C, Saceda-Corralo D, Moreno-Arrones ÓM, et al.

    Journal of the American Academy of Dermatology 2021; (84(5)):1285-1294 doi:10.1016/j.jaad.2020.09.093.

    PMID: 33038469
  5. 5

    Dutasteride in the treatment of frontal fibrosing alopecia: Systematic review and meta-analysis.

    Seo HM, Oh SU, Kim S, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2024; (38(8)):1514-1521 doi:10.1111/jdv.19802.

    PMID: 38357767
  6. 6

    Oral isotretinoin combined with topical clobetasol 0.05% and tacrolimus 0.1% for the treatment of frontal fibrosing alopecia: a randomized controlled trial.

    Mahmoudi H, Rostami A, Tavakolpour S, et al.

    The Journal of dermatological treatment 2022; (33(1)):284-290 doi:10.1080/09546634.2020.1750553.

    PMID: 32238014
  7. 7

    Medical therapy for frontal fibrosing alopecia: A review and clinical approach.

    Ho A, Shapiro J

    Journal of the American Academy of Dermatology 2019; (81(2)):568-580 doi:10.1016/j.jaad.2019.03.079.

    PMID: 30953702
  8. 8

    Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).

    Marmor MF, Kellner U, Lai TY, et al.

    Ophthalmology 2016; (123(6)):1386-94.

    PMID: 26992838
  9. 9

    Isotretinoin as a promising option in the treatment of facial papules of frontal fibrosing alopecia.

    Beyzaee AM, Babaei M, Ghoreishi B, et al.

    International journal of dermatology 2024; (63(12)):1685-1690 doi:10.1111/ijd.17356.

    PMID: 38991994
  10. 10

    JAK Inhibitors in the Treatment of Lichen Planopilaris.

    Nasimi M, Ansari MS

    Skin appendage disorders 2024; (10(1)):10-17 doi:10.1159/000534631.

    PMID: 38313572
  11. 11

    Successful Hair Regrowth in Early Frontal Fibrosing Alopecia With Combination Therapy.

    Kadasa S, Alturkistani M, Aleissa AI, Alsantli A

    Cureus 2026; (18(3)):e104784 doi:10.7759/cureus.104784.

    PMID: 41943777
  12. 12

    Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia.

    Martin A, Shokrian N, Kelley KJ, et al.

    The Journal of investigative dermatology 2026; (146(5)):1265-1270.e7 doi:10.1016/j.jid.2025.09.375.

    PMID: 41101628
  13. 13

    Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review.

    Seale LR, Eglini AN, McMichael AJ

    Journal of drugs in dermatology : JDD 2016; (15(4)):414-9.

    PMID: 27050696
  14. 14

    Finasteride for hair loss: a review.

    Gupta AK, Venkataraman M, Talukder M, Bamimore MA

    The Journal of dermatological treatment 2022; (33(4)):1938-1946 doi:10.1080/09546634.2021.1959506.

    PMID: 34291720
  15. 15

    Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study.

    Melles RB, Jorge AM, Marmor MF, et al.

    Annals of internal medicine 2023; (176(2)):166-173 doi:10.7326/M22-2453.

    PMID: 36645889
  16. 16

    Target in Sight: A Comprehensive Review of Hydroxychloroquine-Induced Bull's Eye Maculopathy.

    Snow Z, Seely K, Barrett S, et al.

    Current ophthalmology reports 2024; (12(3)):38-48 doi:10.1007/s40135-024-00321-6.

    PMID: 39371107
  17. 17

    Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology.

    Bagatin E, Costa CS, Rocha MADD, et al.

    Anais brasileiros de dermatologia 2020; (95 Suppl 1()):19-38 doi:10.1016/j.abd.2020.09.001.

    PMID: 33036809
  18. 18

    Reported psychiatric adverse events among isotretinoin users: Monitoring priorities from a 20-year FDA Adverse Event Reporting System database study.

    Nie W, Wu X, Xia Y, et al.

    Journal of the American Academy of Dermatology 2025; (93(1)):64-72 doi:10.1016/j.jaad.2025.02.072.

    PMID: 40024390
  19. 19

    Isotretinoin musculoskeletahl side effects: a systematic review.

    Almutairi RR, Almutairi AG, Alhallafi AF, et al.

    Dermatology reports 2024; (16(4)):9845 doi:10.4081/dr.2024.9845.

    PMID: 39749120
  20. 20

    The Perception of Contraceptive Practice Among Female Patients Treated With Isotretinoin in Saudi Arabia.

    Almarri FH, Al Dhafiri M, Albejais RA, et al.

    Cureus 2024; (16(9)):e69390 doi:10.7759/cureus.69390.

    PMID: 39411596
  21. 21

    Expert Consensus on the Rational Approach to Isotretinoin Usage for Effective Management of Acne: ERAISE ACNE Recommendations.

    Kandhari S, Thomas J, Khunger N, et al.

    Dermatology and therapy 2026; (16(6)):2607-2638 doi:10.1007/s13555-026-01681-6.

    PMID: 41915360
  22. 22

    Vibration assisted analgesia during intralesional corticosteroid therapy for alopecia.

    Wynne MD, Harries T, Hennegan C, et al.

    Skin health and disease 2024; (4(3)):e363 doi:10.1002/ski2.363.

    PMID: 38846691
  23. 23

    Delineating Injectable Triamcinolone-Induced Cutaneous Atrophy and Therapeutic Options in 24 Patients-A Retrospective Study.

    Sharma RK, Gupta M, Rani R

    Indian dermatology online journal 2022; (13(2)):199-206 doi:10.4103/idoj.idoj_483_21.

    PMID: 35287395
  24. 24

    The safety and efficacy of intralesional triamcinolone acetonide for keloids and hypertrophic scars: A systematic review and meta-analysis.

    Zhuang Z, Li Y, Wei X

    Burns : journal of the International Society for Burn Injuries 2021; (47(5)):987-998 doi:10.1016/j.burns.2021.02.013.

    PMID: 33814214
  25. 25

    Intralesional Corticosteroid Administration in the Treatment of Keloids: A Scoping Review on Injection Methods.

    Yin Q, Louter JMI, Niessen FB, et al.

    Dermatology (Basel, Switzerland) 2023; (239(3)):462-477 doi:10.1159/000529220.

    PMID: 36657423
  26. 26

    Clinical effectiveness of finasteride versus hydroxychloroquine in the treatment of frontal fibrosing alopecia: A randomized controlled trial.

    Saber M, Farokhshahi M, Fatemi Naeini F, et al.

    Journal of cosmetic dermatology 2024; (23(2)):576-584 doi:10.1111/jocd.15993.

    PMID: 37691183

This page is for informational purposes only and does not constitute medical advice. Discuss off-label FFA treatments, pregnancy precautions, and eye or laboratory monitoring with your healthcare clinician.

Guide contents Frontal fibrosing alopecia
Research & Literature
03 How FFA is Diagnosed 05 Building Your Care Team and Preparing for Visits